Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

This prospective, multicenter, single-arm, open-label Phase III study aimed to evaluate the efficacy and safety of Privigen® (10% liquid human intravenous immunoglobulin [IVIG], stabilized with l-proline) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Patients received on...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Léger, Jean-Marc, De Bleecker, Jan L, Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Mielke, Orell, Tackenberg, Björn, Shebl, Amgad, Bauhofer, Artur, Zenker, Othmar, Merkies, Ingemar S J
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley Periodicals, Inc. 2013
Témata:
Research Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3910165/
https://ncbi.nlm.nih.gov/pubmed/23781960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jns5.12017
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky